...
首页> 外文期刊>Pain medicine : >The abuse potential of Remoxy((R)), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone.
【24h】

The abuse potential of Remoxy((R)), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone.

机译:与速释和缓释羟考酮相比,羟考酮的缓释制剂Remoxy(R)有滥用的可能性。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: Remoxy((R)) is a water-insoluble, highly viscous oral formulation of oxycodone extended release (ER) currently in development. The primary objective was to determine the abuse potential of Remoxy under fed conditions relative to oxycodone ER and immediate release (IR) under fasted conditions and compared with placebo (treatment group X). A secondary objective was to evaluate abuse potential under reversed fed/fasted conditions (treatment group Y). DESIGN: Phase I randomized double-blind triple-dummy placebo- and active-controlled 6-way crossover study. Setting. A single US site. PATIENTS. Healthy men and women aged 18-50 years who were nondependent, recreational opioid users. Interventions. Remoxy 40 mg whole and chewed, oxycodone ER 40 mg whole and crushed, oxycodone IR 40 mg crushed, and placebo. OUTCOME MEASURES: The primary endpoint was the drug liking subscale of the drug effects questionnaire assessed by various pharmacodynamic parameters. Secondary endpoints included additional pharmacodynamic measures, chewing duration, and safety measures. RESULTS: In treatment group X, Remoxy whole (fed) and chewed (fed) had a significantly lower abuse potential compared with oxycodone ER (crushed, fasted) and IR (fasted) based on the majority of pharmacodynamic parameters of interest for the primary endpoint (drug liking subscale) as well as secondary endpoints. Treatment group Y showed generally similar results. CONCLUSIONS: The abuse potential of Remoxy when taken whole or chewed was significantly lower than two comparators with known abuse potential, including oxycodone IR and crushed oxycodone ER, under the fed/fasted conditions tested. Remoxy may be associated with a reduced risk potential for abuse.
机译:目的:Remoxy(R)是目前正在开发中的羟考酮缓释剂(ER)的水不溶性,高粘度口服制剂。主要目的是确定相对于羟考酮ER在喂食条件下雷莫昔的滥用可能性以及在禁食条件下立即释放(IR),并与安慰剂进行比较(治疗组X)。次要目标是评估在相反的进食/禁食条件下的滥用可能性(治疗组Y)。设计:一期随机双盲三重假人安慰剂和主动对照6交叉研究。设置。一个美国站点。耐心。非依赖性,休闲性阿片类药物使用者的健康年龄在18-50岁的男女。干预措施。完全雷莫可40毫克并咀嚼,羟考酮ER 40毫克并粉碎,羟考酮IR 40毫克,压片和安慰剂。观察指标:主要终点是通过各种药效学参数评估的药物疗效问卷的药物偏爱量表。次要终点包括其他药效学措施,咀嚼时间和安全性措施。结果:根据主要终点指标的主要药效学参数,在治疗组X中,瑞可莫全脂(进食)和咀嚼(进食)的滥用潜力明显低于羟考酮ER(压碎,禁食)和IR(禁食) (喜欢毒品的分量表)以及次要指标。 Y治疗组显示出大致相似的结果。结论:在测试的进食/禁食条件下,雷莫克全脂食用或咀嚼时的滥用可能性显着低于两个已知滥用可能性的比较者,包括羟考酮IR和粉碎的羟考酮ER。 Remoxy可能会降低滥用的潜在风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号